PV patients with JAK2 exon 14 mutation do not differ in the number of thrombotic events, risk of leukemic and fibrotic transformation, and overall survival to those with JAK2 exon 12 mutation [8]. This evidence concerns the gene JAK2 and acquired polycythemia vera.